Advanced Esophageal Cancer
Conditions
Brief summary
This study intends to explore the predictive biomarkers by Next-generation sequencing (NGS) and multiple immunohistochemistry (mIHC) for the treatment of SHR-1210 in combination with paclitaxel and platinum in advanced esophageal cancer.
Interventions
DRUGCombination therapy
SHR-1210 (camrelizumab) + albumin-bound paclitaxel + Carboplatin
Sponsors
Nanjing Geneseeq Technology Inc.
Jiangsu HengRui Medicine Co., Ltd.
Sixth Affiliated Hospital, Sun Yat-sen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Unresectable locally advanced/ recurrent or distant metastatic esophageal squamous cell carcinoma confirmed by histology or cytology; * Not received any previous systematic antitumor therapy. * Eastern Cooperative Oncology Group (ECOG) fitness status score was 0 or 1 within 3 days before the first administration of the intervention. * 8-10 tumor tissue samples can be provided. * Demonstrate good organ and bone marrow function. * Consent to participate in the contraceptive methods related to clinical research.
Exclusion criteria
* Have a history of allergy to monoclonal antibodies, any component of SHR-1210, albumin-paclitaxel, carboplatin, and other platinum drugs; * Weight loss \> 20% in the past 3 months. * Major surgery within 28 days prior to enrollment. * Have received systemic chemotherapy or radiation therapy for esophageal cancer. * Had a myocardial infarction within the past 6 months. * Have any medical history or current evidence, treatment, or laboratory abnormalities that prevent the subject from participating fully in the study with the investigator's opinion. * Prior treatment with immunotherapy drugs. * Received live vaccine within 30 days prior to initial administration of the investigational drug. * Have been diagnosed with immunodeficiency or are receiving immunosuppressive treatment. * Another malignancy is known to exist. * Have active infections that require systemic treatment. * Pregnant or lactating, or planning to become pregnant or become a father during the study period (180 days for lactating subjects receiving carboplatin) from the beginning of the screening visit until 120 days after the last dose of the study intervention.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | up to approximately 1 year | ORR is determined using RECIST v1.1, defined as best overall response (CR or PR) across all assessment time points during the period from enrolment to termination of trial treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) | up to approximately 1 year | It is defined as the time from enrollment to the first occurrence of disease progression as determined by the investigator with use of RECIST v1.1 or death from any cause, whichever occurs first. Patients who have not experienced disease progression or death at the time of analysis will be censored at the time of last tumor assessment. |
| Overall Survival (OS) | up to approximately 1 year | Defined as the time from the enrollment to death from any cause |
| Disease Control Rate (DCR) | up to approximately 1 year | The proportion of patients who have achieved complete response， partial response and Stable disease assessed by investigators according to Recist v 1.1. |
| Adverse events (AEs) | up to approximately 1 year | All adverse event/Serious adverse event that occurred during the study period according to CTCAE v 4.03 |
Countries
China
Contacts
Primary ContactHongying Liao, Professor
Outcome results
None listed